Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 17;17(28):6866-6871.
doi: 10.1039/c9ob01068h.

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO

Affiliations

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO

N V S Dinesh K Bhupathiraju et al. Org Biomol Chem. .

Abstract

The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(iv) and, more importantly, the radioisotope 89Zr for use in radiolabeling antibodies for positron emission tomography (PET) imaging. Previous studies of 89Zr-HOPO-trastuzumab in mice showed low background, good tumor to organ contrast, and very low bone uptake which show p-SCN-Bn-HOPO to be an important next-generation bifunctional chelator for radioimmunoPET imaging with 89Zr. However, the reported synthesis of p-SCN-Bn-HOPO involves nine steps and multiple HPLC purifications with an overall yield of about 1.4%. Herein we report an improved and efficient synthesis of p-SCN-Bn-HOPO in four steps with 14.3% overall yield which will improve its availability for further biological studies and wider application in PET imaging. The new synthetic route also allows variation in linker length and chemistries which may be helpful in modifying in vivo clearance behaviors of future agents.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Chemical structures of the 89Zr complexes with bifunctional p-SCN-Bn-HOPO (left) and p-SCN-Bn-DFO (right) ligands.
Scheme 1
Scheme 1
Four step synthesis of p-SCN-Bn-HOPO. (a) 2-(4-teritiarybutyl aminophenyl)ethyl 4-methylbenzenesulfonate, K2CO3, CH3CN, reflux, 8–10 h (b) 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid chloride, NEt3, DMAP, dichloromethane, 0−25 °C, 24 h, (42% over 2 steps); (c) BCl3 in p-xylene, dichloromethane, −20 °C to RT, overnight, 95%; (d) di-2-pyridyl thiocarbonate, NEt3, CH3CN, H2O, r.t, 1 h, 36%.
Scheme 2
Scheme 2
Improvements to the original 9-step synthesis of p-SCN-Bn-HOPO are outlined in red. (a) Ethyl trifluoroacetate, MeOH, −78 °C, 1 h; (b) (BOC)2O, MeOH, r.t, 18 h; (c) conc. NH4OH, r.t, 15 h (52% over 3 steps); (d) 4-nitrophenethyl 4-methylbenzenesulfonate, K2CO3, CH3CN, reflux, 12 h, 46%; (e) 4 M HCl in Dioxane, r.t, 2 h; (f) 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid chloride, NEt3, DMAP, dichloromethane, 0−25 °C, 12 h, 56% (over 2 steps); (g) Raney Ni, H2, MeOH, 3 h; (h) BCl3 in p-xylene, dichloromethane, −20 °C to RT, 15 h, 99%; (i) di-2-pyridyl thiocarbonate, NEt3, CH3CN, H2O, r.t, 1 h, 36%.

References

    1. Bhatt NB, Pandya DN and Wadas TJ, Molecules, 2018, 23, 638/631–638/624. - PMC - PubMed
    1. Deri MA, Zeglis BM, Francesconi LC and Lewis JS, Nuclear Medicine and Biology, 2013, 40, 3–14. - PMC - PubMed
    1. Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE and Dongen GAMS, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 250–259. - PMC - PubMed
    1. Guérard F, Lee Y-S and Brechbiel MW, Chemistry – A European Journal, 2014, 20, 5584–5591. - PMC - PubMed
    1. Guerard F, Lee Y-S, Tripier R, Szajek LP, Deschamps JR and Brechbiel MW, Chemical Communications, 2013, 49, 1002–1004. - PMC - PubMed

Publication types

MeSH terms